Clinical Trial Update: A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating HB-202/HB-201 with pembrolizumab in HPV16-positive recurrent/metastatic oropharyngeal squamous cell carcinoma has been withdr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• HB-201
• HB-202
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Hookipa Biotech GmbH | Conditions: Oropharyngeal Squamous Cell Carcinoma Recurrent | Phase 2, Phase 3 | Status: WITHDRAWN